{"id":10521,"date":"2010-06-01T16:33:49","date_gmt":"2010-06-01T16:33:49","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=10521"},"modified":"2010-06-01T16:33:49","modified_gmt":"2010-06-01T16:33:49","slug":"raltegravir-and-unboosted-atazanavir","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/10521","title":{"rendered":"Raltegravir and unboosted atazanavir"},"content":{"rendered":"<p><strong>www.hiv-druginteractions.org<\/strong><\/p>\n<p>Coadministration of raltegravir (400 mg twice daily) and unboosted atazanavir (300 mg twice daily) was studied in 22 HIV-positive volunteers. Raltegravir pharmacokinetics were compared to historical data from HIV-positive volunteers receiving 10 day raltegravir monotherapy.<\/p>\n<p>Raltegravir geometric mean AUC with atazanavir was 6166 ng.h\/ml and was comparable to historical controls (6851 ng.h\/ml). Atazanavir exposure showed high inter subject variability with a geometric mean AUC of 14622 ng.h\/ml and a CV of 68.3%. Linear regression showed a highly significant correlation between raltegravir AUC and atazanavir AUC: subjects with atazanavir AUC &gt;14622 ng.h\/ml had a two-fold increase in raltegravir AUC. A similar trend was observed for trough concentrations.<\n\nOverall, unboosted atazanavir did not significantly increase raltegravir exposure, although subjects with higher atazanavir exposure had higher raltegravir concentration.\n\n\n\n\n<h2>comment<\/h2>\n<\/p><p><strong>Raltegravir pharmacokinetics are variable and this is a cross study comparison; therefore we need to be cautious in interpreting the data.<\/strong><\/p>\n<p>Ref: Cattaneo D et al. Exposure-related effects of unboosted atazanavir on the pharmacokinetics of raltegravir in HIV-1 infected patients. 11th PK Workshop, 2010. Abstract 49.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>www.hiv-druginteractions.org Coadministration of raltegravir (400 mg twice daily) and unboosted atazanavir (300 mg twice daily) was studied in 22 HIV-positive volunteers. Raltegravir pharmacokinetics were compared to historical data from HIV-positive volunteers receiving 10 day raltegravir monotherapy. Raltegravir geometric mean AUC &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,34],"tags":[134],"class_list":["post-10521","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-pk-and-drug-interactions","tag-pk-workshop-11th-2010"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/10521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=10521"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/10521\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=10521"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=10521"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=10521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}